TransMedics Group posts $0.44 EPS short of estimates as targets shift
TransMedics Group reported quarterly EPS of $0.44, missing analysts’ $0.50 consensus, and the stock fell about 2.1%. Brokerages maintained mixed views: Canaccord and TD Cowen reiterated buy ratings with targets near $120, while UBS cut its target to $77 and kept a neutral stance. Average recommendations stayed at Hold.